Project Grant HT94252510125

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $144,362 to Georgia Tech Research Corporation to conduct a multi-year research project focused on investigating the effectiveness and mechanisms of lymphaticovenous anastomoses (LVA) for treating lymphedema. The research aims to gain deeper insights into the biomechanics and adaptations of the lymphatic system in response to...

Larix Bioscience LLC received a $245,728 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports the company's research and development of novel therapies for improving lymphatic dysfunction, a complication commonly associated with obesity and diabetes. Specifically, the grant funds the generation and preclinical evaluation of albumin and Fc fusion protein therapeutics targeting adrenomedullin...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $116,278 to the University of South Florida to investigate the plasminogen activator pathway and its role in the development of lymphatic malformations. The research aims to 1) assess the expression of key plasminogen activator enzymes and their activation of matrix metalloproteinases, and 2) attempt to rescue lymphatic valve...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $340,956 to Agex Therapeutics Inc. to develop novel, highly regenerative, and scalable progenitor cell exosomes for treating peripheral artery disease (PAD). The goal of this Phase I Small Business Innovation Research (STTR) project is to demonstrate the therapeutic feasibility of using exosomes derived from Agex's proprietary PureStem...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...

This federal Project Grant award, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research aimed at elucidating the pathophysiology of lymphatic malformations (LM), a common vascular condition in children. The $189,750 award to Seattle Children's Hospital will support a 1-year research project that combines spatial transcriptomics and single-cell genotyping to investigate how a small number of...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to improve the robustness and reproducibility of manufacturing human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) through the development of feedback-controlled closed-loop processes. The $590,283 award to the University of Wisconsin-Madison will support research to: 1) identify key differentiation failure modes through single-cell...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $750,162 to The Children's Hospital of Philadelphia (CHOP) to conduct research on lymphatic dysfunction and the development of post-lung transplant obliterative bronchiolitis. The key objectives are to: 1) determine the mechanisms of lymphatic vascular function after lung transplantation, 2) develop strategies to promote lymphangiogenesis...

This federal Project Grant award, totaling $508,436, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding supports research at the University of Texas Southwestern Medical Center to investigate the "two-hit" model for lymphatic malformations, a type of rare vascular disease. The key objectives are to examine the role of the KRAS oncogene and VEGF-C growth factor in the development of...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $751,983 to The Trustees of Columbia University in the City of New York to develop an inhalable stem cell exosome therapy for cardiac injury treatment. The key objectives are to: 1) establish the therapeutic benefits of repeated inhalation delivery of lung spheroid cell-derived exosomes in a mouse model of myocardial infarction (MI), 2)...